Symbols

COYA

Coya Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About COYA

Coya Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing proprietary new therapies to enhance regulatory T cell function

Industry

Life Science Tools and Services

Established Date

Listing Date

12/29/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.coyatherapeutics.com

Security Type

Common stock

Office address

5850 San Felipe St. Suite 500, Houston, TX 77057

Business

Introduction

Coya Therapeutics, Inc., was incorporated under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing patented drugs to regulate the function of sex T cells. Tregs is a subset of T lymphocytes composed of CD4 + CD25 high hFOXP 3 + cells that inhibit inflammation. Tregs and their transcription factors are essential for maintaining homeostasis by regulating autoimmune and inflammatory responses and maintaining mammalian self-tolerance. Treg dysfunction is an important part of the pathophysiology of severe neurodegenerative diseases, autoimmune diseases and metabolic diseases, and the company believes that there is an urgent need for new and effective treatments.

Company Financials

EPS

COYA has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.3, beating expectations. The chart below visualizes how COYA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

COYA has released its 2025 Q3 earnings report, with revenue of 3.56M, reflecting a YoY change of NaN%, and net profit of -2.12M, showing a YoY change of 47.39%. The Sankey diagram below clearly presents COYA's revenue sources and cost distribution.